In particular, specific efforts are mandatory and aim to identify the cases who need to be redirected or not to an allogeneic stem cell transplantation (Allo-HSCT) and/or to a targeted therapy with FLT3 or other specific pathway’s inhibitors, since this form of leukemia showed a high plasticity and chemoresistance at relapse [18]. This evidence concerns the gene FLT3 and leukemia.